TY - BOOK ID - 6717907 TI - Pharmaceutical patents in Europe PY - 2000 SN - 9041113487 9004481478 PB - Leiden; Boston : Brill | Nijhoff, DB - UniCat KW - Drugs KW - Medicaments KW - Medications KW - Medicine (Drugs) KW - Medicines (Drugs) KW - Pharmaceuticals KW - Prescription drugs KW - Bioactive compounds KW - Medical supplies KW - Pharmacopoeias KW - Chemotherapy KW - Materia medica KW - Pharmacology KW - Pharmacy KW - Biotechnology. KW - Octrooirecht. KW - Chemical engineering KW - Genetic engineering KW - Patents. KW - Droits intellectuels KW - Protection des médicaments KW - Produits pharmaceutiques KW - Certificat complémentaire de protection KW - Brevet européen UR - https://www.unicat.be/uniCat?func=search&query=sysid:6717907 AB - The pharmaceutical industry and patent legislation are inextricably linked. Pharmaceutical companies could not exist without some guarantee that they can recoup the cost of developing a new product. European patent law offers this opportunity, as it allows companies to exclude competition for a specific product for a fixed time scale. In Pharmaceutical Patents in Europe the current legal patent situation is examined by a detailed analysis of case law from the European Patent Office (EPO), the international body created with the signing of the European Patent Convention (EPC). Aspects of European patent law not primarily regulated in the EPC, for example Supplementary Protection Certificates and infringement matters, are examined in the setting provided by EC law and domestic laws of European states. This book is written for the reader who understands the main characteristics of patent law and is looking for a practitioner's text on the European pharmaceutical patent law scene. Moreover, the author's remarks can help all readers to look at the field with fresh eyes. ER -